TB-500 Reconstitution Calculator

No. TB-500 lacks approval for human therapeutic use in any jurisdiction, and full-length Tβ4 is likewise unapproved. Human orthopaedic efficacy data are lacking. Full-length recombinant Tβ4 has one human RCT (96 STEMI patients), where early post-PCI dosing reduced infarct area in a subgroup, but this is investigational, not approval. TB-500 is banned in sport under WADA Class S0 ("unapproved substances").

Tβ4 is the natural 43-amino-acid actin-sequestering peptide. TB-500 is the synthetic N-acetylated 17–23 fragment (LKKTETQ), the molecule's actin-binding core. Nearly all repair literature tested full Tβ4; direct TB-500 evidence is restricted to a single study in an 80-study scoping review. Transfer of Tβ4 findings to TB-500 is mechanistically plausible but not empirically established.

No human pharmacokinetic or route-comparison data exist. The rat Achilles tendon model used 60 µg/kg/day intraperitoneally for 4 weeks, with significant biomechanical benefit (animal). Subcutaneous and intramuscular injection are the standard community routes (community protocol). Across the animal literature, dosing and route are highly heterogeneous. TB-500 is not used orally: gastrointestinal degradation precludes it (mechanistic); investigational delivery includes topical hydrogels.

No human safety data exist. Pregnancy: no data, avoid. Cancer history: Tβ4 signaling drives cell migration and blood vessel growth (angiogenesis); Tβ4 overexpression promotes breast cancer proliferation, migration, and EMT, so use with an undiagnosed malignancy is a theoretical risk. Surgery: no studies evaluate perioperative wound complications, hematoma, or infection risk from TB-500; a conservative perioperative approach is advised.

Unknown: no human duration studies. Animal protocols typically run 4 weeks. Most-used community regimen is 2.0–2.5 mg twice weekly for 4–8 week cycles with off-periods (community protocol). Any use is incompatible with WADA-sanctioned competition.

Head-to-head rat Achilles transection (animal): TB-500 60 µg/kg/day produced significantly higher load-to-failure at 4 weeks plus improved Bonar/Movin histology scores versus control; BPC-157 10 µg/kg/day trended better without statistical significance; the combination added no benefit over either alone. Mechanistically BPC-157 acts mainly via angiogenesis, TB-500/Tβ4 via actin regulation and cell migration. Neither compound has adequate human RCT data for musculoskeletal injuries.

Stability: TB-500 degrades completely in serum within one week at 4–22°C and remains stable ≥2 months at −20°C; dried-blood-spot samples stay detectable without refrigeration. Store lyophilized vials frozen; refrigerate reconstituted solution and use within days-to-weeks (community protocol). Drug testing: LC-MS methods detect TB-500 in human blood matrices and equine urine/plasma, so treat it as detectable in doping control.